Predictors of Aspirin Failure in Preeclampsia Prevention

Recruiting now · Early Phase 1

Conditions studied: Preeclampsia

In brief

Hypertensive disorders of pregnancy (including preeclampsia) are among the leading causes of pregnancy complications and maternal deaths worldwide. They also increase the risks to the babies. Numerous interventions have been suggested in order to reduce the rate of preeclampsia. Low-dose aspirin is the most beneficial prophylactic approach in this regard. Nevertheless, aspirin failure is not uncommon. The genetic, laboratory, and clinical factors associated with low-dose aspirin failure in the prevention of preeclampsia are largely unknown. The presence of a genetic variant in PAR4 receptor expressed on platelets, is associated with increased platelet function and possibly with aspirin failure.

Key facts

Study ID

NCT05709483

Run by

Rockefeller University

People needed

130

Starts

2023-04-13

Expected to finish

2026-11-01

Last updated by the study team

2025-10-30

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Women aged 18-45 years with prior history of preeclampsia who received low dose aspirin in their subsequent gestation and either did or did not have a recurrence of preeclampsia.
• Aspirin was given in their subsequent pregnancy in a 81 mg dose prior to 16 weeks of gestation, and was taken with a self-reported compliance rate of at least 80%
• Subsequent pregnancy lasted beyond 20 weeks of gestation
• Willingness to abstain from non-prescription non-steroidal anti-inflammatory drugs (NSAIDs), which are known to interfere with platelet function assays, for one week prior to platelet function analyses.
• Healthy controls recruited for SNP assay optimization:
• Women aged 18 years or older, with no other specific inclusion criteria that need to be met in order to be enrolled for the study.

You may not qualify if…

• Age <18 years or >45 years
• Any clinically significant adverse reaction to aspirin on prior exposure
• Known bleeding disorder based on personal or family history
• History of kidney or liver impairment
• Current pregnancy
• Current use of antithrombotic agents (e.g., aspirin, clopidogrel, warfarin, direct acting oral anticoagulants).
• Chronic hypertension (systolic blood pressure >140 mmHG or diastolic pressure >90 mmHG, or use of antihypertensive drugs or diagnosis made by clinician)
• Diabetes mellitus
• Current known malignancy
• History of hemorrhagic stroke
• Participants may be excluded at the discretion of the investigator for medical, psychological or other reasons
• Rockefeller students, and Rockefeller employees in the Coller lab, are excluded from participation.
• Healthy controls:
• A. <18 years of age. B. Participants may be excluded at the discretion of the investigator for medical, psychological or other reasons C. Rockefeller students, and Rockefeller employees in the Coller lab, are excluded from participation.

Where it is running

• Rockefeller University — New York, New York, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.